Centers of Excellence
Upper Tract Urothelial Carcinoma
Throughout 2019, we have continued to see progress in the diagnosis, risk assessment and genetic profiling, and possible treatment of upper tract urothelial carcinoma (UTUC). I would like to highlight some of the most exciting findings reported so far this year.
Targetable mutations in UTUC: At the Fred Hutchinson Cancer Research Center and the University of Washington, Dr. Brian R. Winters, Dr. Andrew
Sam S. Chang, MD, MBA, Patricia and Rodes Hart Endowed Professor of Urologic Surgery and Oncology, is the Oncology Fellowship Director and Vice-Chair of Urologic Surgery at Vanderbilt University Medical Center. His clinical practice focuses on urologic oncology and he has led numerous guideline panels in prostate, bladder and kidney cancer and formerly chaired the American Joint Committee on Cancer GU Staging Task Force. Author of more than 275 articles and recipient of multiple awards such as the SUO’s first-ever Distinguished Service Award, a CaPCURE Prostate Cancer Young Investigator Award, multiple Journal of Urology Best Reviewer, and the AUA Gold Cystoscope Award, he currently serves as Assistant Secretary of the AUA.
Upper Tract Urothelial Carcinoma Today: 2019
Upper tract urothelial carcinoma (UTUC) comprises 5% to 10% of urothelial carcinomas, is distinct from bladder cancer, and often carries a worse prognosis — roughly 60% of patients present with invasive disease. Until recently, the relative rarity of UTUC and difficulties with accurate pre-operative staging impeded clinical trials and therapeutic progress.